icon
icon
Overview

Pleural mesothelioma is a rare cancer that develops from the mesothelial cells lining the lungs and inner chest wall. It is also called diffuse pleural mesothelioma and was previously commonly described as malignant pleural mesothelioma.

The disease usually grows as multiple areas of tumour across the pleural surface rather than as a single lung mass. Over time, it can thicken and encase the lung, invade the chest wall, diaphragm or nearby organs, and spread to lymph nodes or distant parts of the body.

Exposure to asbestos is the principal known risk factor. Mesothelioma often develops several decades after the exposure occurred, and some patients do not recall any direct contact with asbestos. The disease is different from lung cancer, although both can cause similar respiratory symptoms.

At Apollo Cancer Centres (ACC), pleural mesothelioma care is planned by a multidisciplinary team involving thoracic surgeons, medical oncologists, radiation oncologists, pulmonologists, interventional pulmonologists, radiologists, nuclear-medicine specialists, pathologists, pain specialists, and supportive-care professionals. Treatment is individualised according to the tumour's subtype, stage, resectability, symptoms, lung function, and the patient's overall health.

Risk Factors for Pleural Mesothelioma

Most cases of pleural mesothelioma are associated with previous asbestos exposure. However, not everyone exposed to asbestos develops the disease, and some patients have no recognised exposure.
Factors associated with an increased risk include:
Occupational asbestos exposure

Occupational Asbestos Exposure

People who worked in construction, shipbuilding, insulation, mining, manufacturing, railways, power plants, demolition, brake repair, or asbestos-product industries may have been exposed.
Environmental Asbestos Exposure

Environmental Asbestos Exposure

Living near asbestos mines, factories, naturally occurring asbestos deposits, or contaminated buildings can increase risk.
Secondary Household Exposure

Secondary Household Exposure

Family members may previously have been exposed to asbestos fibres carried home on a worker's clothing, hair, shoes, or equipment.
Long Interval After Exposure

Long Interval After Exposure

Mesothelioma commonly develops 20 to 50 years or more after asbestos exposure, so the original contact may be difficult to recall.
Amount and Duration of Exposure

Amount and Duration of Exposure

Greater cumulative exposure generally increases risk, although mesothelioma can occasionally occur after lower-level exposure.
Previous Radiation Therapy

Previous Radiation Therapy

Radiation to the chest for another cancer may rarely contribute to mesothelioma years later.
Inherited BAP1 Tumour-Predisposition Syndrome

Inherited BAP1 Tumour-Predisposition Syndrome

Germline changes in the BAP1 gene increase the risk of mesothelioma, uveal melanoma, kidney cancer, and certain other tumours.
Family History

Family History

Mesothelioma or BAP1-associated cancers in close relatives may indicate an inherited susceptibility.
Increasing Age

Increasing Age

The disease is more frequently diagnosed in older adults because of its long latency period.
Male Sex

Male Sex

Pleural mesothelioma has historically been more common in men because occupational asbestos exposure was more frequent in male-dominated industries.
Certain Mineral Fibres

Certain Mineral Fibres

Exposure to erionite and selected other naturally occurring fibrous minerals has been associated with mesothelioma in particular regions.
Smoking is not considered a direct cause of mesothelioma. However, smoking and asbestos exposure together substantially increase the risk of lung cancer, and stopping smoking can improve breathing and treatment tolerance.

Pleural Mesothelioma Signs and Symptoms

Symptoms often develop gradually as the pleura thickens, fluid collects around the lung, or the tumour restricts lung expansion and invades nearby structures.
Possible signs and symptoms include:

Increasing shortness of breath

Persistent chest pain or discomfort

Pain beneath the ribs or around the shoulder

A persistent dry cough

Chest heaviness or tightness

Reduced ability to take a deep breath

Recurrent fluid around the lung

Fatigue or reduced stamina

Unexplained weight loss

Reduced appetite

Fever or night sweats

Hoarseness or a change in voice

Difficulty swallowing

Swelling of the face, neck, or arm

A lump or swelling on the chest wall

Reduced movement on one side of the chest

Abdominal swelling or discomfort

Persistent back pain

Bone pain or neurological symptoms in advanced disease

These symptoms are more commonly caused by other conditions. Persistent breathlessness, chest pain, unexplained pleural fluid, or symptoms in a person with previous asbestos exposure should be investigated.

How Pleural Mesothelioma Is Diagnosed

Diagnosis begins with a detailed medical and occupational history. The doctor asks about current symptoms and possible asbestos exposure through work, home renovation, family members, residential areas, or previous industries. Because the exposure may have occurred decades earlier, a careful lifetime history is useful.

The chest and lymph nodes are examined, and breathing function is assessed. Imaging may suggest mesothelioma, but tissue biopsy is generally required because pleural thickening and fluid can also result from infection, inflammation, metastatic cancer, or another pleural disease.

• •

Chest X-Ray

A chest X-ray may show fluid around one lung, pleural thickening, reduced lung volume, or another chest abnormality. It is often the first investigation performed for breathlessness or chest pain. These findings are not specific to mesothelioma. CT is required to evaluate the pleura and surrounding structures in greater detail.

Contrast-Enhanced CT

Contrast-enhanced CT of the chest and upper abdomen is the main initial imaging test. It can show nodular pleural thickening, a pleural mass, encasement of the lung, fluid, chest-wall invasion, enlarged lymph nodes, and possible spread below the diaphragm. CT helps identify an appropriate biopsy site and evaluate whether surgery may be technically possible. However, imaging alone cannot reliably distinguish mesothelioma from other pleural cancers or determine every area of invasion.

PET-CT

PET-CT can help evaluate the extent of metabolically active disease, identify lymph-node or distant metastases, and select a biopsy site. It is particularly useful when treatment with curative intent or major surgery is being considered. Recent pleural procedures, pleurodesis, infection, and inflammation can cause increased tracer uptake and complicate interpretation. The timing of the scan and the patient's procedural history must therefore be considered.

MRI

MRI provides detailed assessment of soft tissues and may be used when involvement of the chest wall, diaphragm, spine, blood vessels, or mediastinal structures is uncertain. It can support surgical and radiation planning in selected patients. MRI is complementary to CT rather than routinely required for every case.

Brain Imaging

Brain metastases are less common at diagnosis than in many lung cancers. Brain MRI or CT may be performed when neurological symptoms are present, advanced disease is suspected, or imaging is required for a particular treatment plan.

Lung-Function Assessment

Pulmonary-function tests measure airflow, lung capacity, and gas transfer. They help determine how much the disease has affected breathing and whether a patient could tolerate major surgery or thoracic radiation. Exercise testing, arterial blood-gas measurement, perfusion scanning, or cardiopulmonary exercise testing may be added before extensive surgery. Functional assessment is particularly important because mesothelioma and pleural fluid can substantially restrict lung expansion.

Cardiac Assessment

ECG, echocardiography, stress testing, or another cardiac evaluation may be required before major surgery or systemic treatment. Mesothelioma can occasionally involve structures close to the heart, and the proposed treatment may place additional strain on the cardiovascular system.

Thoracentesis

Thoracentesis uses a needle or catheter to remove fluid from around the lung. The procedure can improve breathlessness and provide fluid for cytological examination. Pleural-fluid cytology may detect cancer cells, but it often cannot diagnose or accurately subtype mesothelioma. A negative fluid result does not exclude the disease, and tissue biopsy is frequently required.

Image-Guided Pleural Biopsy

Ultrasound or CT can guide a core needle into an area of pleural thickening or a pleural mass. Several samples may be obtained to provide enough tissue for histology and immunohistochemistry. Image-guided biopsy may be suitable for patients who cannot undergo thoracoscopy or when there is a clear accessible target. Small samples may not always demonstrate invasion or represent the full tumour.

Medical Thoracoscopy

Medical thoracoscopy allows a pulmonologist to examine the pleural cavity through a small incision and obtain multiple biopsies under direct vision. It is commonly performed with local anesthesia and sedation. The procedure can also drain pleural fluid and perform pleurodesis when appropriate. Direct visualisation improves the likelihood of obtaining adequate representative tissue.

Video-Assisted Thoracoscopic Surgery

Video-assisted thoracoscopic surgery allows a thoracic surgeon to inspect the pleura and obtain larger tissue samples under general anesthesia. It may be used when medical thoracoscopy is unsuitable or when another surgical procedure is planned. The biopsy pathway is selected carefully because tumour can occasionally grow along an instrument or incision tract. Modern practice does not routinely require preventive radiation to every procedure tract.

Lymph-Node Biopsy

Endobronchial ultrasound may be used to sample mediastinal or hilar lymph nodes. Ultrasound-guided biopsy can assess accessible neck or supraclavicular nodes. Mediastinoscopy or another surgical biopsy may occasionally be required when precise lymph-node staging is essential before a major operation.

Biopsy of Metastatic Disease

A suspected distant metastasis may be biopsied when confirmation will affect staging or treatment. The site is selected according to accessibility, safety, and the amount of tissue required.

Laboratory

Biopsy tissue is examined by a pathologist experienced in thoracic and mesothelial tumours.

Assessment may include:

  • Histological confirmation: Demonstrates an invasive mesothelial cancer and distinguishes it from reactive pleural changes and cancers that have spread to the pleura.

  • Histological subtype: Classifies the tumour as epithelioid, biphasic, or sarcomatoid.

  • Epithelioid subtype: Usually has a more favourable prognosis and may be more suitable for multimodality treatment in selected patients.

  • Biphasic subtype: Contains both epithelioid and sarcomatoid components. The proportion of each component may be reported.

  • Sarcomatoid subtype: Generally behaves more aggressively and is less likely to benefit from major surgical resection.

  • Tumour grade: Nuclear features and mitotic activity may be assessed for epithelioid mesothelioma.

  • Growth pattern: Architectural patterns may provide additional diagnostic and prognostic information.

  • Lymphovascular and perineural invasion: Records spread into blood vessels, lymphatic channels, or nerves.

  • Margin assessment: Determines whether tumour reaches the edge of a surgically removed specimen.

  • Lymph-node assessment: Reports the number and location of lymph nodes examined and involved.

  • Mesothelial markers: Calretinin, WT1, D2-40, and cytokeratin 5/6 may support mesothelial differentiation.

  • Carcinoma markers: Claudin-4, MOC31, BerEP4, TTF-1, Napsin A, and other markers help exclude metastatic lung or other epithelial cancers.

  • BAP1 assessment: Loss of BAP1 expression can support a malignant mesothelial diagnosis and may raise concern for an inherited BAP1 alteration in the appropriate clinical setting.

  • MTAP assessment: Loss of MTAP expression may support malignancy in selected mesothelial proliferations.

  • CDKN2A testing: Fluorescence in-situ hybridisation may identify deletion of CDKN2A and help distinguish malignant mesothelioma from reactive mesothelial cells.

  • PD-L1 testing: May provide additional information but is not universally required to select standard first-line immunotherapy.

  • Molecular profiling: Broad tumour profiling may be considered in advanced disease, an unusual pathological setting, or for clinical-trial eligibility.

Blood tests may include a complete blood count, kidney and liver function tests, electrolytes, coagulation profile, and lactate dehydrogenase. These tests cannot diagnose mesothelioma but help assess the patient and plan treatment.

Blood biomarkers such as mesothelin-related peptides cannot independently confirm or exclude mesothelioma and are not substitutes for biopsy. Their routine role in diagnosis and surveillance remains limited.

Germline genetic counselling and testing may be considered for patients diagnosed at a young age, those with little or no recognised asbestos exposure, multiple primary cancers, loss of BAP1 in the tumour, or a family history suggestive of BAP1 tumour-predisposition syndrome.

Staging of Pleural Mesothelioma

Pleural mesothelioma is staged using the tumour–node–metastasis system. Staging considers how extensively the tumour involves the pleural surfaces and nearby structures, whether regional lymph nodes contain cancer, and whether distant metastases are present.

  • Stage I: Stage I disease is confined to the pleura on one side of the chest. It may involve the pleura lining the chest wall, mediastinum, diaphragm, or lung surface without regional lymph-node or distant spread.

  • Stage II: Stage II disease has extended more deeply into nearby tissues or involves regional lymph nodes within the chest, depending on the precise TNM category. It has not spread to distant organs.

  • Stage III: Stage III mesothelioma has more extensive local invasion or greater regional lymph-node involvement. It may involve structures such as the chest wall, mediastinal tissues, diaphragm, pericardium, or nearby lymph nodes.

  • Stage IV: Stage IV disease has invaded critical structures that cannot be completely treated surgically, has extensive lymph-node involvement, or has spread to distant organs.

Clinical stage is based on imaging and biopsy. Pathological stage can be determined more precisely when surgery and lymph-node assessment are performed.

Pleural Mesothelioma Pleural Mesothelioma

How Pleural Mesothelioma Is Treated

• •

Pleurectomy and Decortication

Pleurectomy and decortication removes visible tumour from the pleural surfaces while preserving the lung. The operation may include removal of part or all of the pleura and tumour covering the lung, chest wall, diaphragm, or mediastinum. An extended procedure may also remove and reconstruct involved portions of the diaphragm or pericardium. The objective is macroscopic complete resection rather than removal of every microscopic cancer cell. This is a major operation with risks including bleeding, infection, air leak, heart complications, and reduced respiratory function. It should be considered only after multidisciplinary assessment at an experienced thoracic centre.

Extrapleural Pneumonectomy

Extrapleural pneumonectomy removes the affected lung together with the pleura and usually parts of the diaphragm and pericardium. Reconstruction of the diaphragm and pericardium is then performed. The procedure carries substantial risks and is now used only in exceptional, highly selected circumstances. Lung-preserving approaches are generally preferred when surgery forms part of the treatment plan.

Lymph-Node Assessment

Regional lymph nodes are sampled or removed during definitive surgery. Nodal involvement influences stage, prognosis, and the need for additional treatment. Disease in certain lymph-node regions may indicate that major surgical resection is unlikely to provide sufficient benefit.

Palliative Surgical Procedures

Surgical or thoracoscopic procedures may be used to control recurrent pleural fluid, re-expand the lung, obtain tissue, or relieve selected symptoms. These procedures are intended to improve comfort and breathing rather than remove all disease.

Platinum and Pemetrexed Chemotherapy

A platinum medicine combined with pemetrexed is a standard systemic treatment for pleural mesothelioma. It may be used for unresectable disease, around surgery in selected multimodality programmes, or when immunotherapy is unsuitable. Carboplatin may be used instead of cisplatin when kidney function, hearing, nerve health, age, or general condition makes cisplatin less suitable. Vitamin supplementation is required with pemetrexed to reduce toxicity. Bevacizumab may be added for selected patients when there is no significant bleeding, clotting, cardiovascular, or wound-healing concern and when it is appropriate within the treatment setting.

Dual-Checkpoint Immunotherapy

Combination immune-checkpoint therapy targeting PD-1 and CTLA-4 may be used as a first-line treatment for unresectable pleural mesothelioma. It is particularly important for non-epithelioid disease, although treatment is individualised. Immunotherapy helps the immune system recognise and attack cancer cells. Some patients achieve prolonged disease control. Immune-related adverse effects may involve the lungs, bowel, liver, skin, thyroid, pituitary gland, kidneys, heart, nervous system, or other organs. Symptoms require prompt assessment and may need corticosteroids or other immune-suppressing treatment.

Chemoimmunotherapy

An immune-checkpoint inhibitor combined with platinum–pemetrexed chemotherapy may be considered for eligible patients with unresectable advanced or metastatic pleural mesothelioma. The choice between chemoimmunotherapy, dual immunotherapy, or chemotherapy depends on histology, disease burden, symptoms, autoimmune conditions, organ function, treatment availability, and regulatory approval.

Treatment Around Surgery

Chemotherapy or immunotherapy may be given before or after surgery within selected multidisciplinary treatment plans. The optimal sequence is not identical for every patient and continues to evolve. Major surgery should not be undertaken without a clear plan for systemic treatment, radiation when indicated, and management of potential complications.

Treatment After Progression

When the cancer progresses, options depend on previous treatment, duration of response, histology, symptoms, and performance status. Treatment may include pemetrexed-based therapy if not previously used, immunotherapy, another chemotherapy medicine, rechallenge with a previous regimen, or a clinical trial. Repeat biopsy or molecular profiling may be considered when the diagnosis is uncertain or trial eligibility depends on a particular finding.

Postoperative Radiation Therapy

Radiation may be considered after surgery when there is a substantial risk of local recurrence or when margins contain tumour. The role depends on the operation performed, disease distribution, previous treatment, and the ability to protect the remaining lung and other organs. After lung-preserving surgery, radiation planning is particularly complex because the intact lung is sensitive to radiation. Treatment is undertaken only when the expected benefit outweighs the risk.

Definitive Radiation Therapy

Radiation may be used as the primary local treatment for selected unresectable tumours, particularly when disease is confined to a manageable area or when systemic therapy has achieved good control. Intensity-modulated radiation therapy, image guidance, respiratory motion management, and selected use of proton therapy can help limit exposure to the lungs, heart, esophagus, liver, spinal cord, and kidneys.

Palliative Radiation Therapy

Radiation is commonly used to relieve chest-wall pain, painful tumour masses, bleeding, airway compression, or symptoms caused by bone or other metastases. The number of sessions is tailored to the site, symptoms, previous radiation, general health, and treatment goals.

Procedure-Tract Radiation

Preventive radiation to biopsy, thoracoscopy, or drainage tracts is not routinely recommended for every patient. A tract-site tumour that develops later can be treated if it causes pain or another problem.

Pleural Mesothelioma
Prognosis for Pleural Mesothelioma

The outlook varies according to the stage, histological subtype, lymph-node involvement, resectability, treatment response, and general health. Pleural mesothelioma is often diagnosed after it has spread across the pleural surface, making complete eradication difficult.

Epithelioid mesothelioma generally has a more favourable outlook than biphasic or sarcomatoid disease. Selected patients with localised epithelioid tumours may achieve prolonged control with multimodality treatment.

Factors influencing prognosis include:
Stage at diagnosis
Epithelioid, biphasic, or sarcomatoid histology
Proportion of sarcomatoid tumour in biphasic disease
Regional lymph-node involvement
Invasion of the chest wall, diaphragm, pericardium, or mediastinal structures
Distant metastases
Ability to achieve macroscopic tumour removal
Response to immunotherapy or chemotherapy
Lung and heart function
Performance status
Weight loss and nutritional condition
Blood-cell counts and inflammatory markers

Follow-up generally includes clinical review and periodic CT imaging. Additional imaging is performed when symptoms or findings suggest progression.

Pleural fluid, pain, breathlessness, treatment effects, and nutritional needs are reassessed throughout follow-up so that supportive treatment can be adjusted promptly.

Why Choose ACC for Pleural Mesothelioma Treatment

Multidisciplinary care involving thoracic surgery, medical oncology, radiation oncology, pulmonology, radiology, pathology, and palliative care

Detailed occupational and asbestos-exposure assessment

Contrast-enhanced CT, PET-CT, MRI, and cardiopulmonary evaluation

Medical thoracoscopy, video-assisted biopsy, and image-guided pleural biopsy

Specialist thoracic pathology and mesothelioma immunohistochemistry

BAP1, MTAP, CDKN2A, and molecular assessment where indicated

Lung-preserving pleurectomy and decortication for selected patients

Chemotherapy, dual immunotherapy, and chemoimmunotherapy

Image-guided radiation and proton therapy for selected cases

Pleurodesis and indwelling pleural-catheter management

Interventional pain treatment, pulmonary rehabilitation, and nutritional care

Structured imaging surveillance and early supportive-care integration
Frequently Asked Questions
01 Is pleural mesothelioma the same as lung cancer?
icon icon
No. Mesothelioma begins in the lining around the lung, while lung cancer begins within lung tissue or the airways. Their pathology, staging, and treatment differ.
02 Is pleural mesothelioma always caused by asbestos?
icon icon
Most cases are associated with asbestos exposure, but some patients do not recall exposure or develop the disease because of other factors.
03 How long after asbestos exposure can mesothelioma develop?
icon icon
The disease commonly appears 20 to 50 years or more after exposure. This long delay can make the original source difficult to identify.
04 Can family members of asbestos workers be at risk?
icon icon
Yes. In the past, family members could be exposed to fibres brought home on work clothing, shoes, hair, or equipment.
05 Does smoking cause mesothelioma?
icon icon
Smoking is not considered a direct cause of mesothelioma. However, smoking and asbestos exposure together greatly increase the risk of lung cancer.
06 Can pleural-fluid testing diagnose mesothelioma?
icon icon
It can occasionally identify the cancer, but fluid cytology is often insufficient. A tissue biopsy is usually required to confirm the diagnosis and subtype.
07 What are the main types of pleural mesothelioma?
icon icon
The main histological subtypes are epithelioid, biphasic, and sarcomatoid. These differ in behaviour, prognosis, and suitability for some treatments.
08 Is surgery suitable for every patient?
icon icon
No. Surgery is considered only for selected patients with technically resectable disease, suitable histology, adequate heart and lung function, and sufficient overall fitness.
09 Can pleural mesothelioma be cured?
icon icon
Cure is uncommon, but selected patients with localised disease may achieve prolonged control through multimodality treatment. Systemic and supportive treatments can also control advanced disease and relieve symptoms.
10 Is immunotherapy used for mesothelioma?
icon icon
Yes. Dual-checkpoint immunotherapy or immunotherapy combined with chemotherapy may be used for eligible patients with unresectable or metastatic disease.
11 How is recurrent pleural fluid managed?
icon icon
Options include pleurodesis or an indwelling pleural catheter. The choice depends on whether the lung can re-expand, symptoms, general health, and patient preference.
12 Should relatives undergo genetic testing?
icon icon
Not routinely. Genetic counselling may be appropriate when the patient is unusually young, has no recognised asbestos exposure, has several BAP1-associated cancers, or has a suggestive family history.
image image
Book an Appointment
Please Enter Your Name
Please Enter Your Mobile Number
Please Enter OTP